Among these RNA therapeutics, Eteplirsen and Golodirsen influence the splicing of dystrophin to treat Duchenne muscular dystrophy (DMD), while Nusinersen promotes a full-length splice variant of SMN2 mRNA that is effective in reducing the symptoms associated with spinal muscular atrophy (SMA). Here, SMN2 is linked to Duchenne muscular dystrophy.